Gain insights from our experts...
Optimizing lipid nanoparticles (LNPs) processing for siRNA delivery by microfluidics system
The success of mRNA vaccines during the COVID-19 pandemic has accelerated the advancement of nucleic acid delivery technologies. In addition to mRNA, interfering RNA offers potential to treat diseases beyond the reach of small molecules. However, therapeutic success hinges on efficient and targeted delivery systems. Lipid nanoparticles (LNPs), especially those produced via microfluidics, have emerged as a leading platform for RNA delivery. delivery. for RNA.
Join Dr. Qiaobin Hu as he explores LNP formulation for siRNA delivery using a microfluidic flow-focusing system.
Optimising lipid nanoparticles (LNPs) processing for siRNA delivery by microfluidics system
866.3 KB
Explore our poster presentation with Qiaobin Hu
Explore additional content
Explore recent blogs:
The Nitrosamine challenge in pharmaceuticals
Since 2018 the risk of nitrosamine impurities in medicinal products has become a critical concern for pharmaceutical manufacturers and regulators alike
Gain insights from our experts...
Explore our poster: Optimising lipid nanoparticles (LNPs) processing for siRNA delivery by microfluidics system. The success of mRNA vaccines during the COVID-19 pandemic has accelerated the...
Croda celebrates opening of expanded UK facility, bolstering global Super Refined™ capabilities
Croda International Plc (“Croda”), the company that uses smart science to create high-performance ingredients and pharmaceutical excipients that improve lives, celebrated the opening of its newly...